Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. The company focuses on therapies targeting the cough reflex arc.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.